Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance

PloS One
Mahiul M K MuqitHelen Buck

Abstract

To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacular traction (VMT) with and without full thickness macular holes (FTMH) treated according to NICE guidance. Retrospective observational case series of 25 patients treated with a single intravitreal ocriplasmin injection between December 2013 and December 2015. Best corrected visual acuity and optical coherence tomography exams were performed to determine visual outcomes and anatomical VMT release and FTMH closure over time. Two patient groups were identified: ocular macular co-morbidity (OCM) and no OCM (nOCM), with follow-up at 4, 12, and 24 weeks. Twenty-five patients were identified that included 19 patients with VMT, and 6 patients with VMT plus FTMH. In the nOCM group of 22 patients, the release rate of VMT was 44%, 63%, and 69% at 4, 12 and 24 weeks respectively. In the "real-world" OCM group of 25 patients, the VMT release rate was 37%, 53%, and 58% at the same time-points. In both groups, the FTMH closure rate was 33%, 50%, and 67% at 4, 12, and 24 weeks. At mean follow-up of 30 weeks in the VMT group with nOCM, the mean LogMAR VA improved significantly from 0.44 to 0.28 (p = 0.0068, paired t-test). Three were no serious ...Continue Reading

References

Sep 7, 2006·Postgraduate Medical Journal·S M SalviZ Currie
Nov 21, 2012·American Journal of Ophthalmology·Ian A RodriguesTimothy L Jackson
Jan 15, 2013·American Journal of Ophthalmology·Mark W Johnson
Jun 10, 2015·Ophthalmic Surgery, Lasers & Imaging Retina·Jonathan H TzuJeffrey G Gross
Feb 24, 2016·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Peter Stalmans
Aug 23, 2016·Ophthalmic Surgery, Lasers & Imaging Retina·Timothy L JacksonUNKNOWN MIVI-TRUST Study Group

❮ Previous
Next ❯

Citations

Feb 8, 2019·Current Pharmaceutical Design·Christine P S Ho, Timothy Y Y Lai
Jan 15, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Souska ZandiJustus G Garweg
Aug 1, 2020·European Journal of Ophthalmology·Brian Edward YuMonali S Malvankar-Mehta
Jun 5, 2020·Retina·David H W SteelUNKNOWN INJECT study investigators

❮ Previous
Next ❯

Software Mentioned

MIVI
VMT
Prism
GraphPad
TRUST

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

© 2022 Meta ULC. All rights reserved